Skip to main content
Terug
AGIO logo

Agios Pharmaceuticals, Inc.

Datakwaliteit: 100%
AGIO
NASDAQ Healthcare Biotechnology
€ 28,35
▲ € 0,24 (0,85%)
Marktkapitalisatie: 1,66B
Dagbereik
€ 27,46 € 28,65
52-Weeksbereik
€ 22,24 € 46,00
Volume
750.001
50D / 200D Gem.
€ 28,20 / € 33,93
Vorige Slotkoers
€ 28,11

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E -4,0 0,3
P/B 1,4 2,9
ROE % -30,2 3,7
Net Margin % -764,0 3,8
Rev Growth 5Y % 10,0
D/E 0,1 0,2

Koersdoel Analisten

Hold
€ 41,50 +46.4%
Low: € 25,00 High: € 62,00
Forward WPA
-€ 6,63
Omzet Sch.
91 M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 -€ 0,06
-€ 0,09 – -€ 0,04
670 M 6
FY2029 -€ 2,35
-€ 3,33 – -€ 1,35
500 M 6
FY2028 -€ 3,42
-€ 5,01 – -€ 1,10
370 M 8

Belangrijkste Punten

Earnings declined -161,27% over the past year
Debt/Equity of 0,05 — conservative balance sheet
Negative free cash flow of -377,29M
PEG of 0,02 suggests growth is underpriced
Capital efficient — spends only 7,99% of revenue on capex

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)48,03%
Earnings (1Y)-161,27%
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-30,20%
ROIC-28,21%
Net Margin-764,01%
Op. Margin-873,87%

Veiligheid

Debt / Equity
0,05
Current Ratio11,46
Interest Coverage0,00

Waardering

P/E Ratio
-4,02
P/B Ratio1,39
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 48,03% Revenue Growth (3Y) 41,92%
Earnings Growth (1Y) -161,27% Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 54,03M Net Income (TTM) -412,78M
ROE -30,20% ROA -31,82%
Gross Margin 88,26% Operating Margin -873,87%
Net Margin -764,01% Free Cash Flow (TTM) -377,29M
ROIC -28,21% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,05 Current Ratio 11,46
Interest Coverage 0,00 Dividend Yield 0,00%
Valuation
P/E Ratio -4,02 P/B Ratio 1,39
P/S Ratio 30,74 PEG Ratio 0,02
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 1,66B Enterprise Value 1,63B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 54,03M 36,50M 26,82M 14,24M 0,0
Net Income -412,78M 673,73M -352,09M -231,80M 1,60B
EPS (Diluted) -7,12 11,64 -6,33 -4,23 -6,36
Gross Profit 47,68M 32,33M 17,32M 12,54M -18,78M
Operating Income -472,13M -425,74M -391,49M -389,05M -378,42M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1,30B 1,66B 937,12M 1,24B 1,44B
Total Liabilities 104,11M 122,24M 126,10M 137,90M 145,76M
Shareholders' Equity 1,19B 1,54B 811,02M 1,10B 1,29B
Total Debt 62,02M 56,99M 72,00M 85,66M 97,09M
Cash & Equivalents 89,13M 76,25M 88,21M 139,26M 203,13M
Current Assets 942,05M 965,60M 833,84M 832,77M 1,06B
Current Liabilities 82,21M 81,16M 67,96M 62,63M 59,83M